Dr. Ralf Gold discuses the current and future treatment landscape for patients with Multiple Sclerosis while at ECTRIMS 2015 in Barcelona, Spain.
Additional Resources:
Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) markers are exclusive and appropriate factors to monitor the new aim of ‘no evidence of disease activity’ (NEDA). Click here to read article in Therapeutic Advances in Neurologic Disorders: Towards the implementation of ‘no evidence of disease activity’ in multiple sclerosis treatment: the multiple sclerosis decision model
Early identification of suboptimal responses to multiple sclerosis treatment is critical for optimizing subsequent therapeutic decisions. The Rio Score is a scoring system that consists of clinical and MRI parameters to predict suboptimal response. The Modified Rio score is a simplified version of the Rio Score, excluding expanded disability status scale progression and modified items of relapses and MRI lesions. The following articles can provide additional information.
Measures in the first year of therapy predict the response to interferon beta in MS
Scoring treatment response in patients with relapsing multiple sclerosis
This interview is supported by an educational grant from Merck KGaA, Darmstadt, Germany.
